NewAmsterdam Pharma Company N.V. Stock Analysis & AI Score
NewAmsterdam Pharma Company N.V. (NAMS) has an ST Score of 47.8 (C+), driven by its Financial Strength (A) and held back by its Growth (D+). Analysts rate it Buy with a $51.33 price target (+125.7% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
NewAmsterdam Pharma Company N.V. (NAMS) has an ST Score of 47.8 (C+), driven by its Financial Strength (A) and held back by its Growth (D+). Analysts rate it Buy with a $51.33 price target (+125.7% upside).
- Strongest
- Financial StrengthA
- Weakest
- GrowthD+
All factor grades
- Financial StrengthA
- ForecastA
- ProfitabilityB-
- ValuationC
- MomentumC-
- GrowthD+
- Piotroski1/9
Contact
NAMS stock: frequently asked questions
What is NAMS's ST Score?
NewAmsterdam Pharma Company N.V. (NAMS) has an ST Score of 47.8 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is NAMS a buy, hold, or sell?
Analysts rate NAMS a Buy, with a price target of $51.33 (+125.7% vs the current price). Our ST Score grades it C+ (47.8/100). The ST Score is a data-driven signal, not a recommendation.
What are NAMS's factor grades?
Valuation C, Profitability B-, Financial Strength A, Momentum C-, Growth D+, Forecast A.
What is NAMS's valuation grade?
NewAmsterdam Pharma Company N.V. (NAMS) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is NAMS's growth grade?
NewAmsterdam Pharma Company N.V. (NAMS) earns a growth grade of D+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is NAMS's profitability grade?
NewAmsterdam Pharma Company N.V. (NAMS) earns a profitability grade of B-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is NAMS's financial strength grade?
NewAmsterdam Pharma Company N.V. (NAMS) earns a financial strength grade of A, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for NAMS?
The average analyst price target for NewAmsterdam Pharma Company N.V. (NAMS) is $51.33 from 10 analysts, which is +125.7% versus the recent price of $22.74.
What is NAMS's Piotroski score?
NewAmsterdam Pharma Company N.V. (NAMS) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.